Related references
Note: Only part of the references are listed.Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR)
Kazuko Sakai et al.
CANCER SCIENCE (2021)
Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis
Masaoki Ito et al.
LUNG CANCER (2020)
Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer
Hirotsugu Kenmotsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer
Xue-Wu Wei et al.
THORACIC CANCER (2020)
ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection
Yi-Long Wu et al.
CLINICAL LUNG CANCER (2018)
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Wen-Zhao Zhong et al.
LANCET ONCOLOGY (2018)
Prognostic value of epidermal growth factor receptor mutations and histologic subtypes with lung adenocarcinoma
Nozomu Motono et al.
MEDICAL ONCOLOGY (2018)
The relationship between EGFR mutation status and clinic-pathologic features in pulmonary adenocarcinoma
Huiyan Deng et al.
PATHOLOGY RESEARCH AND PRACTICE (2018)
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN) a randomised, open-label, phase 2 trial
Dongsheng Yue et al.
LANCET RESPIRATORY MEDICINE (2018)
Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
Frances A. Shepherd et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
Chee Khoon Lee et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)
Catherine Labbe et al.
LUNG CANCER (2017)
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
Chee Khoon Lee et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis
Xiaoli Ma et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers
Aaron M. Chapman et al.
LUNG CANCER (2016)
Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer
Xiaoli Ma et al.
MOLECULAR ONCOLOGY (2014)
Dimeric phenanthroimidazole for blue electroluminescent materials: the effect of substituted position attached to biphenyl center
Zhiming Wang et al.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2014)
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
S. Dearden et al.
ANNALS OF ONCOLOGY (2013)
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
Julien Mazieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)
Koichi Goto et al.
LUNG CANCER (2013)
Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation
Kenichi Suda et al.
CANCER AND METASTASIS REVIEWS (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib
Tona M. Gilmer et al.
CANCER RESEARCH (2008)
Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group
Jean-Pierre Pignon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer
Tetsuya Mitsudomi et al.
CANCER SCIENCE (2007)
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib
Kendall D. Carey et al.
CANCER RESEARCH (2006)
Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors
Katerina Politi et al.
GENES & DEVELOPMENT (2006)
Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor
Kazuko Sakai et al.
FASEB JOURNAL (2006)
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer
T Winton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Share Paper
